Pharma BD Deal Intelligence

Biogen Inc. / Nightstar Therapeutics plc

2019 · Acquisition/Merger · $800M · Complete

Announcement Sentiment

Skeptical

Biogen agreed to acquire Nightstar Therapeutics for $25.50 per share in cash, ~$800M total. Adds two clinical-stage AAV-based gene therapies for inherited retinal disorders: NSR-REP1 for choroideremia and NSR-RPGR for X-linked retinitis pigmentosa. Closed June 7, 2019.

Did it work? Outcome assessment

Strategic verdict

Failed to Achieve

Financial impact

Impaired/Written Down

Pipeline outcome

Assets Terminated

Assessment window: 5yr post-close.

Key facts

Announced Mar 04, 2019
Closed Jun 07, 2019
Deal value $800M
Deal type Acquisition/Merger
Therapeutic area Choroideremia, X-linked retinitis pigmentosa
Indications Choroideremia, X-linked retinitis pigmentosa
Key assets NSR-REP1 (timrepigene emparvovec)
Mechanism AAV gene therapy

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals